BioTuesdays

Tag - Jason Kolbert

Dyadic
Markets

Dawson James halves Dyadic PT to $3

Dawson James halved its price target for Dyadic International (NASDAQ:DYAI) to $3 from $6, citing the company’s C1 platform and whether it will be adopted by a major vaccine maker anytime soon. The stock closed at $2.48...

April 8, 2022
Know Labs
Markets

Dawson James starts Know Labs at buy; PT $7

Dawson James Securities launched coverage of Know Labs (OTCQB:KNWN) with a “buy” rating and price target of $7. The stock closed at $1.59 on Feb. 7. “Know Labs is driving what could be a significant paradigm shift in...

February 8, 2022
Check Cap
Markets

Dawson James ups Check-Cap to buy; PT $1

Dawson James Securities upgraded Check-Cap (NASDAQ:CHEK) to “buy” from “neutral” and maintained its price target of $1. The stock closed at 60 cents on Feb. 4. The company’s C-Scan is a colorectal cancer screening test...

February 7, 2022
BioCardia
Markets

Dawson James ups BioCardia to buy; PT $4

Dawson James upgraded BioCardia (NASDAQ:BCDA) to “buy” with a $4 price target, citing multiple clinical programs in heart failure and a business deal potential. The stock closed at $1.39 on Jan. 21. Analyst Jason...

January 24, 2022
Dyadic
Markets

Dawson James halves Dyadic PT to $6 from $12

Dawson James reduced its price target for Dyadic (NASDAQ:DYAI) to $6 from $12, citing uncertainty about the potential of its COVID-19 vaccine. The stock closed at $3.73 on May 14. “DYAI-100 (COVID) is advancing to human...

May 17, 2021
Aditxt-Logo
Markets

Dawson Jones starts Aditxt Therapeutics at buy; PT $14

Dawson Jones Securities initiated coverage of Aditxt Therapeutics (NASDAQ:ADTX) with a “buy” rating and $14 price target. The stock closed at $3.34 on Feb. 3. Aditxt has developed a unique antibody test that measures a...

February 4, 2021
Mesoblast Logo
Markets

Dawson James starts Mesoblast at buy; PT $14

Dawson James Securities initiated coverage of Mesoblast (NASDAQ:MESO; ASX:MSB) with a “buy” rating and $14 price target. The stock closed at $7.42 on Dec. 18. Mesoblast is using its proprietary technology platform to...

December 19, 2019